A detailed history of Alpha Centric Advisors LLC transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 205,000 shares of FOLD stock, worth $1.95 Million. This represents 1.85% of its overall portfolio holdings.

Number of Shares
205,000
Previous 202,500 1.23%
Holding current value
$1.95 Million
Previous $2.01 Million 9.01%
% of portfolio
1.85%
Previous 1.66%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$9.55 - $12.09 $23,875 - $30,225
2,500 Added 1.23%
205,000 $2.19 Million
Q2 2024

Jul 25, 2024

BUY
$9.04 - $11.75 $248,599 - $323,125
27,500 Added 15.71%
202,500 $2.01 Million
Q1 2024

Apr 24, 2024

BUY
$11.43 - $14.24 $400,050 - $498,400
35,000 Added 25.0%
175,000 $2.06 Million
Q4 2023

Feb 14, 2024

BUY
$9.97 - $14.52 $74,775 - $108,900
7,500 Added 5.66%
140,000 $1.99 Million
Q2 2023

Aug 08, 2023

BUY
$10.72 - $13.3 $1.42 Million - $1.76 Million
132,500 New
132,500 $1.66 Million

Others Institutions Holding FOLD

About AMICUS THERAPEUTICS, INC.


  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.67B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.